SCHEMBL29784646

SCHEMBL29784646

COC(=O)c1cc(F)c2c(c1)CCN1[C@H](C)CC[C@@H]21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.38
▸ POLB P06746 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ XDH P47989 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ FUT7 Q11130 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ HSD17B10 Q99714 2/20 0.35
▸ ALDH1A1 P00352 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22943921 0.85 HDAC6 (0.49) HDAC6
SCHEMBL22943913 0.85 HDAC6 (0.49) HDAC6
SCHEMBL22943908 0.85 HDAC6 (0.49) HDAC6
SCHEMBL22943903 0.85 HDAC6 (0.49) HDAC6
SCHEMBL29672374 0.81 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1HDAC6
SCHEMBL22944117 0.81 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1HDAC6
SCHEMBL29672403 0.81 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1HDAC6
SCHEMBL22944367 0.80 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1NPC1
SCHEMBL22944368 0.80 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1NPC1
SCHEMBL22944361 0.80 HDAC6 (0.41) KDM4EPOLBHSD17B10ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2024-05-30 — — US disclosed
WO-2022169985-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC5 KDM4E 2431/4885POLB 1428/4885LMNA 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback